Rega Institute for Medical Research, University of Leuven, Leuven, Belgium.
PLoS One. 2013 May 28;8(5):e64010. doi: 10.1371/journal.pone.0064010. Print 2013.
Lantibiotics are peptides, produced by bacteria, that contain the noncanonical amino acid lanthionine and many of them exhibit antibacterial activities. The labyrinthopeptin A1 (LabyA1) is a prototype peptide of a novel class of carbacyclic lantibiotics. Here, we extensively evaluated its broad-spectrum activity against HIV and HSV in vitro, studied its mechanism of action and evaluated potential microbicidal applications. LabyA1 exhibited a consistent and broad anti-HIV activity (EC50s: 0.70-3.3 µM) and anti-HSV activity (EC50s: 0.29-2.8 µM) in cell cultures. LabyA1 also inhibited viral cell-cell transmission between persistently HIV-infected T cells and uninfected CD4(+) T cells (EC50∶2.5 µM) and inhibited the transmission of HIV captured by DC-SIGN(+)-cells to uninfected CD4(+) T cells (EC50∶4.1 µM). Time-of-drug addition studies revealed that LabyA1 acts as an entry inhibitor against HIV and HSV. Cellular and virus binding studies combined with SPR/FLIPR technology showed that LabyA1 interacted with the HIV envelope protein gp120, but not with the HIV cellular receptors. LabyA1 also demonstrated additive to synergistic effects in its anti-HIV-1 and anti-HSV-2 activity with anti(retro)viral drugs in dual combinations such as tenofovir, acyclovir, saquinavir, raltegravir and enfuvirtide. LabyA1 can be considered as a novel lead peptide as it had profound antiviral activity against HIV and HSV. Pre-treatment of PBMCs with LabyA1 neither increased the expression of the activation markers CD69 and CD25, nor enhanced HIV replication, nor significantly induced various inflammatory cytokines/chemokines. LabyA1 also did not affect the growth of vaginal Lactobacilli populations. Based on the lack of toxicity on the vaginal Lactobacillus strains and its synergistic/additive profile in combination with clinically approved anti(retro)virals, it deserves further attention as a potential microbicide candidate in the prevention of sexual transmitted diseases.
类细菌素是由细菌产生的肽类物质,含有非典型氨基酸硫醚氨酸,其中许多具有抗菌活性。拉宾肽 A1(LabyA1)是一种新型碳环类细菌素的原型肽。在这里,我们广泛评估了其在体外对 HIV 和 HSV 的广谱活性,研究了其作用机制,并评估了潜在的杀菌应用。LabyA1 在细胞培养物中表现出一致且广泛的抗 HIV 活性(EC50:0.70-3.3 μM)和抗 HSV 活性(EC50:0.29-2.8 μM)。LabyA1 还抑制持续感染 HIV 的 T 细胞与未感染 CD4+T 细胞之间的病毒细胞间传播(EC50:2.5 μM),并抑制被 DC-SIGN+细胞捕获的 HIV 向未感染 CD4+T 细胞的传播(EC50:4.1 μM)。加药时间研究表明,LabyA1 作为 HIV 和 HSV 的进入抑制剂发挥作用。细胞和病毒结合研究结合 SPR/FLIPR 技术表明,LabyA1 与 HIV 包膜蛋白 gp120 相互作用,但不与 HIV 细胞受体相互作用。LabyA1 与抗病毒药物如替诺福韦、阿昔洛韦、沙奎那韦、雷特格韦和恩夫韦肽在双重组合中的抗 HIV-1 和抗 HSV-2 活性具有相加至协同作用。LabyA1 可被视为一种新型的先导肽,因为它对 HIV 和 HSV 具有很强的抗病毒活性。LabyA1 预处理 PBMCs 既不会增加激活标志物 CD69 和 CD25 的表达,也不会增强 HIV 复制,也不会显著诱导各种炎症细胞因子/趋化因子。LabyA1 也不会影响阴道乳酸杆菌种群的生长。由于缺乏对阴道乳酸杆菌菌株的毒性及其与临床批准的抗病毒药物联合使用的协同/相加作用,它值得进一步关注,作为预防性传播疾病的潜在杀微生物候选物。